Direct compression is only considered for vortioxetine hydrobromide after the API lot has been qualified for flow, compressibility, and particle size distribution under Ph. Eur. 2.9.36 and USP <1174>. In a monophasic film-coated tablet with target hardness of 60–100 N and friability below 0.5% after 100 rotations in Ph. Eur. 2.9.7, the formulation may combine directly compressible mannitol at 30–60% w/w, microcrystalline cellulose at 20–50% w/w, sodium starch glycolate at 2–5% w/w, and magnesium stearate at 0.5–1.5% w/w with vortioxetine equivalent to 5 mg, 10 mg, 15 mg, or 20 mg base per unit. The principal process risk is not chemical decomposition but segregation of low-dose API in free-fall transfer. When the final blend is discharged from a bin blender into a tablet press hopper with a drop height greater than 1.5 m, the RSD of content uniformity can rise above 5.0%, and the batch may exceed the USP <905> acceptance value of 15. Compression is therefore run with a densified or pre-compacted API, and ejection force on a rotary press should remain below 10 kN for a 10-mm flat-faced beveled punch to avoid over-lubrication effects. Dissolution is evaluated under USP <711> Apparatus II at 50 rpm in 900 mL of the product-specific FDA dissolution medium. Film-coat suspension is applied in a pan coater with inlet temperature controlled to keep tablet-bed temperature at 38–42 °C. Tablet weight, hardness, thickness, disintegration per USP <701>, and content uniformity are recorded at start-up, middle, and end of compression. Published data for a fixed direct-compression formula are limited to originator regulatory summaries and supplier certificate-of-analysis compendia. Each new API lot therefore requires a pre-compression study rather than direct substitution.

At What Tableting Force Does Roller-Compacted Vortioxetine HBr Become Commercially Robust?

Roller compaction is introduced when direct-compression blends show capping at press speeds above 40 rpm or when the API lot has a Carr Index above 30 under USP <1174>. A pilot-scale roller compactor with ribbed rolls of 200–250 mm diameter and a roll gap of 1.5–2.5 mm is operated at specific roll force of 4–12 kN/cm. The ribbons are milled through an oscillating sieve of 0.8–1.25 mm. The granules are then lubricated with magnesium stearate at 0.5–1.5% w/w and compressed on a rotary tablet press. The process conflict is between ribbon porosity and tablet disintegration. Roll force above 12 kN/cm can produce hard granules with low porosity, and the finished tablet may exceed 15 min disintegration in purified water at 37±2 °C per USP <701>. Below 4 kN/cm, the granule fine fraction increases and low-dose content uniformity may drift outside USP <905>. Ribbon porosity is measured by mercury intrusion or solvent displacement and is maintained between 0.20 and 0.35. Sieve analysis after milling should show at least 70% by weight in the 106–850 µm fraction. On a 45-station rotary machine above 70,000 tablets/h, shortened dwell time increases die-wall friction and can aggravate lamination. Pre-compression and main compression force profiles must therefore be validated. The dry granulation route also lowers the moisture burden to below 1.5% loss on drying, which is advantageous when the final tablet is moisture-sensitive or when a desiccant-free package is required. Degradation products in the granulated intermediate are controlled under ICH Q3B, with unidentified impurities at 0.1% threshold and qualified impurities above that line subject to toxicological qualification. Published commercial-scale data for vortioxetine hydrobromide roller compaction are limited. Process verification across API lots remains mandatory.

Capsule Filling and the Low-Dose Blend Uniformity Margin

Hard hydroxypropyl methylcellulose capsules in size 3 or 4 are used for clinical trial batches and dose titration where tablet tooling is not yet fixed. Vortioxetine hydrobromide is geometrically diluted with lactose monohydrate with particle size d90 ≤ 150 µm. The pre-blend is passed through a 500 µm screen and combined with silicified microcrystalline cellulose and sodium starch glycolate at 2–4% w/w, then lubricated with magnesium stearate at 0.5% w/w. The target fill weight is derived from tapped density, but the controlling release specification is USP <905> with an acceptance value ≤15. On a dosator-type capsule filler running above 6,000 capsules/h, static charge can cause powder to cling to the dosing nozzle and reduce fill weight. Tamping-pin machines may segregate low-dose API if pin pressure is not optimized. In-process samples are drawn at start-up, middle, and end. Any individual content value outside 85.0–115.0% label claim triggers quarantine and rework only under 21 CFR 211.115. Dissolution is performed on capsule contents after shell removal per USP <711>. With hypromellose capsules, gelling or pellicle formation is less likely than with gelatin but can still occur if residual aldehydes from packaging adhesives contaminate the shell. The finished capsule must pass USP <701> disintegration and product-specific dissolution acceptance. Stability is evaluated under ICH Q1A(R2) at 25±2 °C/60±5% RH and 40±2 °C/75±5% RH. Residual solvents are controlled under ICH Q3C, elemental impurities under ICH Q3D, and degradants under ICH Q3B. Capsule brittleness increases when the fill blend moisture is below 1.0% or when the shell is exposed to drying conditions below 20% RH for more than 24 h.

When Vortioxetine Is Formulated as Stick-Pack Granules for Oral Administration

Stick-pack granules are used when patients cannot swallow whole tablets or capsules and require non-standard dose adjustment. A fluid-bed granulator with top-spray insert is operated with inlet air at 55–70 °C, product temperature at 25–35 °C, and atomization air at 1.5–3.0 bar. A hypromellose binder solution at 5% w/v is sprayed at 10–25 g/min for a 5 kg batch. Vortioxetine hydrobromide may be suspended in the binder or layered onto mannitol or sorbitol starter pellets, depending on dose uniformity. The process risk is that aqueous granulation of a poorly soluble salt leads to drug migration to the granule surface during drying. This is controlled by beginning drying with inlet humidity below 35% RH and terminating when loss on drying is 1.0–2.5%. Sieve analysis per USP <786> should place at least 90% of granules between 125 µm and 850 µm. The granules are filled into stick-pack film of polyester/aluminum foil/polyethylene. Seal strength is tested by dye penetration and burst strength under USP <1207>. Dissolution uses USP <711> Apparatus II with a sinker in 0.1 N HCl. The preliminary acceptance criterion is Q=80% in 45 min, but official media must be confirmed against the innovator filing or product-specific database. Residual solvents, degradation products, and elemental impurities are controlled under ICH Q3C, ICH Q3B, and ICH Q3D. If granule moisture exceeds 2.0%, a desiccant is added, and the packaging configuration is re-validated for moisture transport at 40±2 °C/75±5% RH.

What Limits the Injectable Use of Vortioxetine Hydrobromide in Hospital Pharmacy?

Vortioxetine hydrobromide does not have a pharmacopoeial monograph for an approved parenteral finished product. Injectable use is limited to development batches, preclinical safety studies, or hospital pharmacy compounding supported by stability-indicating assays. The first technical barrier is pH-dependent solubility. The hydrobromide salt may dissolve at low pH, but free-base precipitation can occur as the solution is adjusted toward physiological pH. A buffered vehicle of pH 3.5–5.0 is tested to balance solubility and injection pain. Tonicity is adjusted with sodium chloride or dextrose to 270–320 mOsm/kg per USP <785>. The solution is filtered through a 0.22 µm sterilizing-grade filter inside ISO 14644-1:2015 Class 7/Grade C with Class 5/Grade A at the point of fill. Sterility is confirmed by USP <71> with 14-day incubation in soybean-casein digest medium and fluid thioglycollate medium. Endotoxin is controlled by USP <85> with a limit calculated from the maximum total daily dose. For small-volume parenteral use the limit is derived from 5 EU/kg/h or the product-specific calculation. Subvisible particles are measured by USP <788> Method 1 light obscuration with acceptance of ≤6,000 particles ≥10 µm and ≤600 particles ≥25 µm per container for small-volume injections. Visible particles are inspected under USP <790>. A significant incompatibility risk arises with silicone oil in prefilled syringe barrels and with rubber stopper additives that can extract into the vehicle. Extractables and leachables are assessed per USP <1663> and USP <1664>. Terminal moist-heat sterilization above 121 °C is generally avoided because degradation may exceed the qualified impurity threshold under ICH Q3B. Aseptic filtration is preferred. Published data for injectable vortioxetine hydrobromide stability in specific vehicles are limited. Each batch therefore receives a beyond-use date only after forced degradation and container-closure compatibility studies.

Lyophilized presentation is considered only when aqueous solution stability cannot support liquid storage or when long-distance shipping requires reduced mass. A typical lyophilization cycle uses a primary drying shelf temperature of -25 °C to -10 °C and chamber pressure of 50–150 mTorr. Secondary drying is extended until residual moisture is below 1.0% by Karl Fischer titration under USP <921>. The vial headspace is flushed with nitrogen before stoppering to keep residual oxygen below 2.0%. After reconstitution with purified water or 0.9% w/v sodium chloride, the cake must redisperse within 120 seconds with gentle swirling and show no visible particles per USP <790>. The lyophilized formulation may include mannitol as a crystalline bulking agent and trehalose or sucrose as amorphous stabilizers. The ratio is optimized by differential scanning calorimetry and freeze-drying microscopy. Subvisible particle limits follow USP <788>. Container-closure integrity is verified by vacuum decay or helium leak testing with a 5 µm laser-drilled positive control. Bromobutyl rubber stoppers with water vapor transmission rate below 0.2 mg/day/vial at 40 °C/75% RH are used to prevent moisture ingress. Because no commercial lyophilized vortioxetine product is established, scale-up from laboratory units to production freeze dryers requires vial heat transfer coefficient mapping and edge-vial consistency studies. Published data for this specific configuration are limited.